Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon &alpha;-2a on virological and serological responses in chronic hepatitis B patients

doi:10.3748/wjg.v22.i46.10210

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 46

This Article

(238)

(249)

(0)

(7256)

(17)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Control Study

World J Gastroenterol. Dec 14, 2016; 22(46): 10210-10218
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10210

Full Size Figure Download Figure

Figure 2 Hepatitis B surface antigen levels in patients in the PEGylated interferon α-2a group and the entecavir group across therapy. HBsAg: Hepatitis B surface antigen; ETV: Entecavir.

Citation: He LT, Ye XG, Zhou XY. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients. World J Gastroenterol 2016; 22(46): 10210-10218
URL: https://www.wjgnet.com/1007-9327/full/v22/i46/10210.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i46.10210

He LT, Ye XG, Zhou XY. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients. World J Gastroenterol 2016; 22(46): 10210-10218 [PMID: 28028369 DOI: 10.3748/wjg.v22.i46.10210]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.